CR9980A - Imidazolinas 4,4,5,5 tetrasustituidas - Google Patents
Imidazolinas 4,4,5,5 tetrasustituidasInfo
- Publication number
- CR9980A CR9980A CR9980A CR9980A CR9980A CR 9980 A CR9980 A CR 9980A CR 9980 A CR9980 A CR 9980A CR 9980 A CR9980 A CR 9980A CR 9980 A CR9980 A CR 9980A
- Authority
- CR
- Costa Rica
- Prior art keywords
- tetrasustituidas
- imidazolins
- esters
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se proporciona un compuesto de fórmula I y las sales y ésteres farmacéuticamente aceptables del mismo, en el que X1, X2, R1, R2, R3, R4, R5 y R6 se describen aquí. Los compuestos muestran actividad como agentes antitumorales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74122305P | 2005-12-01 | 2005-12-01 | |
US85274706P | 2006-10-19 | 2006-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9980A true CR9980A (es) | 2008-06-18 |
Family
ID=37866229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9980A CR9980A (es) | 2005-12-01 | 2008-05-16 | Imidazolinas 4,4,5,5 tetrasustituidas |
Country Status (18)
Country | Link |
---|---|
US (1) | US7851626B2 (es) |
EP (3) | EP1960368B1 (es) |
JP (1) | JP4870778B2 (es) |
KR (2) | KR20100129331A (es) |
CN (1) | CN101316823B (es) |
AR (1) | AR057990A1 (es) |
AU (1) | AU2006319248B2 (es) |
BR (1) | BRPI0619236A2 (es) |
CA (1) | CA2630410C (es) |
CR (1) | CR9980A (es) |
ES (1) | ES2538714T3 (es) |
HK (1) | HK1126216A1 (es) |
MA (1) | MA31550B1 (es) |
NO (1) | NO20082389L (es) |
NZ (1) | NZ568285A (es) |
RU (1) | RU2442779C2 (es) |
TW (1) | TWI326681B (es) |
WO (1) | WO2007063013A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0717657A2 (pt) * | 2006-10-19 | 2013-12-24 | Hoffmann La Roche | Compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, usos de compostos, métodos para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, displidemia e hipertensão e profilaxia de diabetes do tipo ii |
CN101528710B (zh) * | 2006-10-19 | 2012-11-07 | 弗·哈夫曼-拉罗切有限公司 | 氨基甲基-4-咪唑类 |
JP2010532759A (ja) * | 2007-07-06 | 2010-10-14 | パラテック ファーマシューティカルズ インコーポレイテッド | 置換テトラサイクリン化合物を合成するための方法 |
CA2701932C (en) | 2007-10-09 | 2015-10-20 | F. Hoffmann-La Roche Ag | Chiral cis-imidazolines |
US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
JPWO2009151069A1 (ja) | 2008-06-12 | 2011-11-17 | 第一三共株式会社 | 4,7−ジアザスピロ[2.5]オクタン環構造を有するイミダゾチアゾール誘導体 |
BRPI1007334A2 (pt) | 2009-01-16 | 2016-02-10 | Daiichi Sankyo Co Ltd | composto, inibidor, medicamento, composição farmacêutica, uso de um composto, agente anticâncer,e , método para tratar câncer. |
BR112012008075A2 (pt) * | 2009-08-26 | 2016-03-01 | Novartis Ag | compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4 |
CN104945382B (zh) | 2009-10-14 | 2020-02-07 | 默沙东公司 | 提高p53活性的取代的哌啶和其用途 |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
CA2813256A1 (en) | 2010-09-30 | 2012-04-05 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles |
FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
MX2013006739A (es) | 2010-12-16 | 2013-07-17 | Roche Glycart Ag | Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2. |
WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのmdm2阻害剤としての複素環化合物 |
WO2013062923A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
CA2859385A1 (en) | 2011-12-13 | 2013-06-20 | Buck Institute For Research On Aging | Methods for improving medical therapies |
US9062071B2 (en) | 2011-12-21 | 2015-06-23 | Merck Sharp & Dohme Corp. | Substituted piperidines as HDM2 inhibitors |
US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
TWI654180B (zh) | 2012-06-29 | 2019-03-21 | 美商艾佛艾姆希公司 | 殺真菌之雜環羧醯胺 |
US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
WO2014082889A1 (en) * | 2012-11-28 | 2014-06-05 | F. Hoffmann-La Roche Ag | Novel imidazolines as dual inhibitors of mdm2 and mdmx |
WO2014089124A1 (en) | 2012-12-03 | 2014-06-12 | Cenexys, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
CN103012272B (zh) * | 2012-12-21 | 2015-01-28 | 江苏国泰超威新材料有限公司 | 一种咪唑啉化合物的制备方法 |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
EP2961735B1 (en) | 2013-02-28 | 2017-09-27 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
MX363584B (es) * | 2013-07-03 | 2019-03-27 | Hoffmann La Roche | Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2. |
US9657351B2 (en) | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
SG10201805670QA (en) | 2014-01-28 | 2018-08-30 | Buck Inst Res Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
US9745314B2 (en) | 2014-04-17 | 2017-08-29 | The Regents Of The University Of Michigan | MDM2 inhibitors and therapeutic methods using the same |
EP3319944A4 (en) * | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED PROTEASE MODULATORS AND METHODS OF USE THEREOF |
JP2019522633A (ja) | 2016-05-20 | 2019-08-15 | ジェネンテック, インコーポレイテッド | Protac抗体コンジュゲート及び使用方法 |
KR20200035944A (ko) | 2017-06-16 | 2020-04-06 | 유니티 바이오테크놀로지, 인크. | 약제학적 용도를 위해 에난티오머적으로 순수한 시스-이미다졸린 화합물을 제조하기 위한 합성 방법 |
WO2019195851A1 (en) * | 2018-04-06 | 2019-10-10 | Oncolyze, Inc. | Compositions for use in lysis of selective cancer cells |
KR102039696B1 (ko) | 2018-04-23 | 2019-11-04 | 충남대학교산학협력단 | 세포내 결핵균 제어를 위한 p53 발현 조절 가능한 조성물 (K279-1558) 또는 방법 |
KR102622992B1 (ko) * | 2021-03-29 | 2024-01-10 | 주식회사 퓨전바이오텍 | 이미다졸린 유도체 및 이의 중간체 제조방법 |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02101065A (ja) | 1988-10-06 | 1990-04-12 | Tanabe Seiyaku Co Ltd | イミダゾリン誘導体及びその製法 |
WO1996010019A1 (fr) * | 1994-09-26 | 1996-04-04 | Shionogi & Co., Ltd. | Derive imidazole |
GB2351082A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Synthesis of Cyclic Substituted Amidines |
ES2301717T3 (es) * | 2001-12-18 | 2008-07-01 | F. Hoffmann-La Roche Ag | Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores. |
DE60227108D1 (de) | 2001-12-18 | 2008-07-24 | Hoffmann La Roche | Cis-imidazoline als mdm2-hemmer |
US6878735B2 (en) * | 2002-05-31 | 2005-04-12 | Board Of Trustees Of Michigan State University | Multi-substituted imidazolines and method of use thereof |
US7345078B2 (en) * | 2002-05-31 | 2008-03-18 | The Board Of Trustees Of Michigan State University | NF-κB inhibitors and uses thereof |
US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
CN100465163C (zh) * | 2003-06-17 | 2009-03-04 | 霍夫曼-拉罗奇有限公司 | 顺式-2,4,5-三芳基-咪唑啉类化合物 |
US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
RU2354649C2 (ru) * | 2003-06-17 | 2009-05-10 | Ф.Хоффманн-Ля Рош Аг | Цис-имидазолины в качестве ингибиторов mdm2 |
JP4814228B2 (ja) * | 2004-05-18 | 2011-11-16 | エフ.ホフマン−ラ ロシュ アーゲー | 新規cis−イミダゾリン |
US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
-
2006
- 2006-11-22 NZ NZ568285A patent/NZ568285A/en not_active IP Right Cessation
- 2006-11-22 CA CA2630410A patent/CA2630410C/en not_active Expired - Fee Related
- 2006-11-22 EP EP20060819663 patent/EP1960368B1/en active Active
- 2006-11-22 BR BRPI0619236-0A patent/BRPI0619236A2/pt not_active Application Discontinuation
- 2006-11-22 JP JP2008542723A patent/JP4870778B2/ja not_active Expired - Fee Related
- 2006-11-22 AU AU2006319248A patent/AU2006319248B2/en not_active Ceased
- 2006-11-22 CN CN2006800448100A patent/CN101316823B/zh not_active Expired - Fee Related
- 2006-11-22 KR KR1020107024025A patent/KR20100129331A/ko not_active Application Discontinuation
- 2006-11-22 EP EP09166803A patent/EP2130822A1/en not_active Withdrawn
- 2006-11-22 KR KR1020087013226A patent/KR101109437B1/ko active IP Right Grant
- 2006-11-22 WO PCT/EP2006/068748 patent/WO2007063013A1/en active Application Filing
- 2006-11-22 RU RU2008126383/04A patent/RU2442779C2/ru active
- 2006-11-22 ES ES06819663.3T patent/ES2538714T3/es active Active
- 2006-11-22 EP EP10175570A patent/EP2311814A1/en not_active Withdrawn
- 2006-11-27 US US11/604,558 patent/US7851626B2/en not_active Expired - Fee Related
- 2006-11-29 AR ARP060105272A patent/AR057990A1/es not_active Application Discontinuation
- 2006-11-29 TW TW095144209A patent/TWI326681B/zh not_active IP Right Cessation
-
2008
- 2008-05-16 CR CR9980A patent/CR9980A/es not_active Application Discontinuation
- 2008-05-26 NO NO20082389A patent/NO20082389L/no not_active Application Discontinuation
- 2008-06-02 MA MA30992A patent/MA31550B1/fr unknown
-
2009
- 2009-06-01 HK HK09104901.1A patent/HK1126216A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP4870778B2 (ja) | 2012-02-08 |
TW200804297A (en) | 2008-01-16 |
CA2630410C (en) | 2014-02-25 |
CN101316823A (zh) | 2008-12-03 |
CN101316823B (zh) | 2013-05-22 |
BRPI0619236A2 (pt) | 2011-09-20 |
US7851626B2 (en) | 2010-12-14 |
TWI326681B (en) | 2010-07-01 |
CA2630410A1 (en) | 2007-06-07 |
JP2009517439A (ja) | 2009-04-30 |
EP2311814A1 (en) | 2011-04-20 |
KR20080072894A (ko) | 2008-08-07 |
RU2008126383A (ru) | 2010-01-10 |
WO2007063013A1 (en) | 2007-06-07 |
EP1960368B1 (en) | 2015-05-06 |
RU2442779C2 (ru) | 2012-02-20 |
NZ568285A (en) | 2011-08-26 |
AU2006319248B2 (en) | 2012-09-27 |
AU2006319248A1 (en) | 2007-06-07 |
AR057990A1 (es) | 2008-01-09 |
ES2538714T3 (es) | 2015-06-23 |
KR101109437B1 (ko) | 2012-01-31 |
HK1126216A1 (en) | 2009-08-28 |
MA31550B1 (fr) | 2010-08-02 |
US20070129416A1 (en) | 2007-06-07 |
EP1960368A1 (en) | 2008-08-27 |
NO20082389L (no) | 2008-08-18 |
KR20100129331A (ko) | 2010-12-08 |
EP2130822A1 (en) | 2009-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR9980A (es) | Imidazolinas 4,4,5,5 tetrasustituidas | |
DK2235017T3 (da) | Spiroindolinonderivater som anticancermidler | |
ATE519764T1 (de) | Spiroindolinon-derivate | |
EA200801144A1 (ru) | Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич | |
CY1119049T1 (el) | Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια | |
CR8744A (es) | Compuestos terapeuticos | |
MY160424A (en) | Substituted pyrrolidine-2-carboxyamides. | |
PA8680701A1 (es) | Derivados de oxindol | |
CR11518A (es) | Compuestos de carbamoilo como inhibidores de dgat1 190 | |
HRP20120323T1 (en) | Diarylhydantoin compounds | |
CR10148A (es) | Derivados de las benzamidas y heteroarenos | |
UY33226A (es) | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 | |
BRPI0717266A2 (pt) | Derivados de oxindol | |
UY29963A1 (es) | Compuestos terapéuticos: piridinas y pirazinas como andamios | |
CU23413B7 (es) | Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos | |
UY31546A1 (es) | Derivados bis-(sulfonilamino) en terapia 205 | |
UY29826A1 (es) | Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones | |
ATE495176T1 (de) | Spiroindolinon-derivate | |
TW200745032A (en) | Novel heterobicyclic derivatives | |
ECSP088677A (es) | Piperazinas y piperidinas como potenciadores 157 del mglur5 | |
ATE528290T1 (de) | Spiroindolinon-derivate | |
UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
CO6420347A2 (es) | Derivados de imidazotiazol que tienen estructura de anillo de prolina | |
UY27980A1 (es) | Indoles 2,7-sustituidos | |
AR057885A1 (es) | Acido 1-(1-(2- etoxietil) - 1- etil-7-(4- metilpiridin -2- ilamino)- 1h pirazolo (4,3-d) pirimidin -5- il) piperidina -4- carboxilico y las sales del mismo. composiciones farmaceuticas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |